On World Cancer Research Day, we highlight research aimed at improving treatments for both pediatric and adult cancers through innovative techniques.

The Vall d’Hebron Institute of Research’s Paediatric Cancer and Hematological Diseases Research Group Achieves Promising Results for Acute Graft-Versus-Host Disease.

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

The study, which provides guidelines for the clinical management of these patients, reveals that only children with a recent stem cell transplant or with other additional diseases have a higher risk of complications from COVID-19.

"Generation of a bank of surgical orthotopic PDX (patient-derived xenografts) models within the framework of a personalized medicine program in pediatric cancer" was the awarded work, of the Childhood Cancer and Hematological Diseases Group of VHIR.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

A study, co-led by Vall d’Hebron, has analysed the evolution of clinical trials with children and adolescents with cancer over the last 15 years, with the aim of optimising efficacy and defining lines for further progress.

The research team has shown that inhibiting the TRIB3 protein slows the growth of rhabdomyosarcoma and improves survival in animal models.

Vall d'Hebron presents positive results from two studies in transfusion-dependent thalassaemia and severe bone marrow aplasia at the EBMT Annual Meeting on haematopoietic stem cell transplantation.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

La iniciativa "Sin Piedad" explica la història d'en David, un nen que s'està tractant d'un càncer pediàtric, un exemple d'actitud lluitadora davant la malaltia.

The money will allow research into paediatric nervous system tumours and childhood sarcomas to continue, with the aim of improving children's chances of survival and reducing the side effects of treatment.

The association makes the fifth annual donation of 52,390€ that will finance a project to study new therapies for this childhood tumor.

The BEACON clinical trial, in which Vall d'Hebron participates, has observed that adding Bevacizumab to treatment with different chemotherapy drugs reduces tumor size in a greater number of patients.

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

Dr. Carmen Espejo and Dr. Georgina Arrambide, researchers at Cemcat and Vall d'Hebron Research Institute, are the first authors of the article.

The research findings propose to modify the McDonald 2017 criteria, only in those in whom diagnosis using the current criteria is not possible.

The meeting, held between November 29 and December 2 in Barcelona, brought together experts and opinion leaders in the field of multiple sclerosis from around the world.

The grant program offers young researchers the opportunity to further their training in the field of multiple sclerosis.

During the last year, the collaboration between Vall d’Hebron and ZeClinics has found three nanobody candidates with potent anticancer properties in zebrafish model.

The meeting has been the meeting point of the EpSSG group dedicated to research to improve the treatment of childhood and adolescent soft tissue sarcomas.

The award recognizes people with an outstanding career for their relationship with the University and their social impact.

The list identifies the most influential experts, who are among the 1% most cited in their speciality in several areas of knowledge.

The research team used nanotechnology to deliver the drug directly to liver cells, which eliminated side effects without reducing effectiveness.